Appendix 2—table 34. Antihypertensive Non-user Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users.
| All Antihypertensive Non-users by BP: Unmatched | All Antihypertensive Non-users by BP: Matched | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | BP Non-user | BP User | p-value | All | BP Non-user | BP User | p-value | |||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |||
| All Patients | 1,786,001 | 100.0% | 1,649,985 | 92.4% | 136,016 | 7.6% | 271,448 | 100.0% | 135,724 | 50.0% | 135,724 | 50.0% | ||
| Age | ||||||||||||||
| ≤20 | 16,785 | 0.9% | 16,767 | 1.0% | 18 | 0.0% | <0.001 | 34 | 0.0% | 16 | 0.0% | 18 | 0.0% | 1.00 |
| 21-40 | 146,712 | 8.2% | 146,210 | 8.9% | 502 | 0.4% | 1,009 | 0.4% | 507 | 0.4% | 502 | 0.4% | ||
| 41-50 | 231,312 | 13.0% | 228,725 | 13.9% | 2,587 | 1.9% | 5,163 | 1.9% | 2,577 | 1.9% | 2,586 | 1.9% | ||
| 51-60 | 434,995 | 24.4% | 410,636 | 24.9% | 24,359 | 17.9% | 48,700 | 17.9% | 24,349 | 17.9% | 24,351 | 17.9% | ||
| 61-70 | 459,192 | 25.7% | 404,445 | 24.5% | 54,747 | 40.3% | 109,415 | 40.3% | 54,711 | 40.3% | 54,704 | 40.3% | ||
| 71-80 | 309,898 | 17.4% | 271,617 | 16.5% | 38,281 | 28.1% | 76,139 | 28.0% | 38,070 | 28.0% | 38,069 | 28.0% | ||
| ≥81 | 187,107 | 10.5% | 171,585 | 10.4% | 15,522 | 11.4% | 30,988 | 11.4% | 15,494 | 11.4% | 15,494 | 11.4% | ||
| Gender | ||||||||||||||
| Female | 1,079,468 | 60.4% | 956,403 | 58.0% | 123,065 | 90.5% | <0.001 | 245,537 | 90.5% | 122,762 | 90.4% | 122,775 | 90.5% | 0.93 |
| Male | 706,533 | 39.6% | 693,582 | 42.0% | 12,951 | 9.5% | 25,911 | 9.5% | 12,962 | 9.6% | 12,949 | 9.5% | ||
| Region | ||||||||||||||
| Midwest | 347,103 | 19.4% | 321,267 | 19.5% | 25,836 | 19.0% | <0.001 | 51,638 | 19.0% | 25,819 | 19.0% | 25,819 | 19.0% | 1.00 |
| Northeast | 498,566 | 27.9% | 463,273 | 28.1% | 35,293 | 25.9% | 70,544 | 26.0% | 35,272 | 26.0% | 35,272 | 26.0% | ||
| South | 669,285 | 37.5% | 622,064 | 37.7% | 47,221 | 34.7% | 93,980 | 34.6% | 46,990 | 34.6% | 46,990 | 34.6% | ||
| West | 271,047 | 15.2% | 243,381 | 14.8% | 27,666 | 20.3% | 55,286 | 20.4% | 27,643 | 20.4% | 27,643 | 20.4% | ||
| Insurance | ||||||||||||||
| Commercial | 848,106 | 47.5% | 798,579 | 48.4% | 49,527 | 36.4% | <0.001 | 99,039 | 36.5% | 49,523 | 36.5% | 49,516 | 36.5% | 1.00 |
| Dual | 46,774 | 2.6% | 40,212 | 2.4% | 6,562 | 4.8% | 12,645 | 4.7% | 6,319 | 4.7% | 6,326 | 4.7% | ||
| Medicaid | 406,012 | 22.7% | 381,472 | 23.1% | 24,540 | 18.0% | 49,025 | 18.1% | 24,516 | 18.1% | 24,509 | 18.1% | ||
| Medicare | 485,109 | 27.2% | 429,722 | 26.0% | 55,387 | 40.7% | 110,739 | 40.8% | 55,366 | 40.8% | 55,373 | 40.8% | ||
| PCP Visit 2019 | ||||||||||||||
| No | 719,756 | 40.3% | 676,255 | 41.0% | 43,501 | 32.0% | <0.001 | 86,956 | 32.0% | 43,478 | 32.0% | 43,478 | 32.0% | 1.00 |
| Yes | 1,066,245 | 59.7% | 973,730 | 59.0% | 92,515 | 68.0% | 184,492 | 68.0% | 92,246 | 68.0% | 92,246 | 68.0% | ||
| Continuous Outcomes | ||||||||||||||
| mean | SD | mean | SD | mean | SD | p-value | mean | SD | mean | SD | mean | SD | p-value | |
| CCI | 0.96 | 1.66 | 0.96 | 1.65 | 0.88 | 1.76 | <0.001 | 0.88 | 1.75 | 0.88 | 1.74 | 0.88 | 1.75 | 0.76 |
BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation.